Get the Stockscreener App
4.1903
2.57%
-0.1197
X 4 Pharmaceuticals Inc stock is traded at $4.1903, with a volume of 265.62K.
It is down -2.57% in the last 24 hours and up +0.22% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.31
Open:
$4.24
24h Volume:
265.62K
Relative Volume:
0.60
Market Cap:
$395.67M
Revenue:
$35.11M
Net Income/Loss:
$-79.20M
P/E Ratio:
-0.9662
EPS:
-4.3367
Net Cash Flow:
$-88.62M
1W Performance:
+3.94%
1M Performance:
+0.22%
6M Performance:
+33.31%
1Y Performance:
+23.51%
1-Day Range:
$4.1362
$4.33
1-Week Range:
$3.97
$4.36
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.195 | 406.52M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
436.21 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.67 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
838.05 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.00 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.41 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - TradingView
Recursion (NASDAQ: RXRX) director sells 40,000 shares in planned trade - Stock Titan
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
X4 Pharmaceuticals' June 4 Jefferies talk to stream online - Stock Titan
XFOR Q1 2026 Earnings: EPS Beats Estimates Despite Continued Pre-Revenue Status; Stock DeclinesQuarterly Earnings Report - thelegaladvocate.com
Layoff Tracker: J&J trims New Jersey headcount by 56 - BioSpace
Torrent Pharmaceuticals Ltd. Hits All-Time High of Rs 4,698.8 as Momentum Builds Across Timeframes - Markets Mojo
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) CEO receives share grants under 2026 equity plan - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress - Yahoo Finance
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now - sharewise.com
Can Encompass Health's Expansion Strategy Make It a Hold for Now? - TradingView
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now - Yahoo Finance
X4 Pharmaceuticals (XFOR) corrects director nominee and expands equity plan - Stock Titan
X4 Pharma CFO Kirske sells $72,820 in common stock - Investing.com
X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation - Stock Titan
[144] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Shareholders at X4 Pharmaceuticals (NASDAQ: XFOR) approve equity plan - Stock Titan
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
XFOR (X4 Pharmaceuticals) beats Q1 2026 EPS estimates by 21.6 percent, shares climb 3 percent.Collaborative Trading Signals - newser.com
How X4 Pharmaceuticals (XFOR) is positioning for the next five years (Bearish Sentiment) 2026-05-08Shared Momentum Picks - newser.com
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
CapEx per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 Pharmaceuticals, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
EBIT per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 pharmaceuticals incmay offer up to $300 million of common stock, preferred stock, debt securities, warrants, and/or unitsSEC filing - marketscreener.com
X4 Pharmaceuticals IncMay Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or UnitsSEC Filing - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) files $300M shelf; $75M ATM with Jefferies - Stock Titan
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI - Quiver Quantitative
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):